Abstract

Background: Patients undergoing autologous stem cell transplantation (SCT) for myeloma usually undergo disease evaluation approximately 100 days after the SCT. Decisions regarding post transplant consolidation strategies such as tandem transplantation and maintenance therapies are usually taken at the time of this evaluation. It is not clear how often patients continue to have a drop in their M protein after day 100 in the absence of additional therapy.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.